Genomics Research

 
Stock Quotes for Genomics Research top ^
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Aggressive Growth
Sign-up for ghdx investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Aggressive Growth
Sign-up for ghdx investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for rosg investment picks
  • Industry: Business Services
  • Sector: Industrials
  • Stock Type: Cyclical
Sign-up for dnag investment picks

 
ETF Quotes for Genomics Research top ^
  • Holdings: Top Holdings PBE More..., Regeneron Pharmaceuticals, Inc., Biogen Idec Inc, Life Technologies Corp, Gilead Sciences Inc, Amgen Inc
  • Category: Health
  • Morningstar Rating: 2 Stars
Sign-up for pbe investment picks

 
News Articles for Genomics Research top ^
2013/5/8
Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting First-of-its-Kind, Biopsy-Based Test Developed and Validated in Seven Studies Including More Than 1,100 Patients SAN DIEGO , May 8, 2013 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) is making its Oncotype DX® prostate cancer test available to physicians and their patients today following the presentation by the University of California, San Francisco (UCSF) of a positive clinical validation study at the 2013 American Urological Association (AUA) Annual Meeting in San Diego.
Sign-up for Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Invasive Treatments investment picks
2013/2/25
Results Presented at the 14th Annual Advances in Genome Biology and Technology Meeting Reveal Novel Method for RNA-Sequencing and Mutation Identification REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology investment picks
2013/5/2
Findings Demonstrate Utility of Oncotype DX® to Guide Radiation Treatment Decision for DCIS Patients and Support Expanded Access and Reimbursement REDWOOD CITY, Calif.
Sign-up for Genomic Health and ECOG-ACRIN Cancer Research Group Announce Publication of Positive DCIS Validation Study in the Journal of the National Cancer Institute investment picks
2013/3/15
New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients Results Reinforce Oncotype DX as the Only Genomic Test to Guide Chemotherapy Decisions REDWOOD CITY, Calif.
Sign-up for Genomic Health Presents Twenty Two International Studies Demonstrating Worldwide Adoption and Value of Oncotype DX® Breast Cancer Test investment picks
2013/1/30
REDWOOD CITY , Calif., Jan.
Sign-up for Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6, 2013 investment picks
2013/5/1
Complete Results from UCSF-Led Validation Study to be Presented Earlier that Day at the American Urological Association (AUA) Annual Meeting in San Diego Collaborators from the University of California, San Francisco (UCSF) and the Cleveland Clinic to Join Management Team REDWOOD CITY,Calif., May 1, 2013 /PRNewswire/ --  Genomic Health, Inc.   (Nasdaq: GHDX) today announced that it will host an investor webcast and conference call to discuss the positive development and clinical validation study results of its biopsy-based Oncotype DX prostate cancer test on Wednesday, May 8, 2013 at 1:00 p.m. Pacific Time .
Sign-up for Genomic Health Announces Investor Webcast and Conference Call to Review Positive Clinical Validation and Development of the Oncotype DX® Prostate Cancer Test on Wednesday, May 8, 2013 investment picks
2013/4/3
Complete Results from Positive Clinical Validation Study to be Presented at 2013 American Urological Association (AUA) Annual Meeting Company to Make Oncotype DX Prostate Cancer Test Available to Physicians and Prostate Cancer Patients by End of Second Quarter REDWOOD CITY, Calif.
Sign-up for Genomic Health to Address One of the Most Significant Needs in Men's Health with the Oncotype DX® Prostate Cancer Test investment picks
2013/5/2
Product Revenue Increased 8% Compared to Prior Year Oncotype DX® Prostate Cancer Test to be Available Immediately Following Presentation by UCSF Investigators of their Landmark Clinical Study Results at AUA on Wednesday, May 8 Oncotype DX DCIS Clinical Validation Study Scheduled to Publish Online in Journal of the National Cancer Institute Today 10 Abstracts Accepted for Presentation at ASCO, Highlighting Breast, Colon and Prostate Progress Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces First Quarter 2013 Financial Results and Business Progress investment picks
2013/3/13
Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy Oncotype DX DCIS validation study accepted by peer-reviewed journal for publication in coming months REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Results from Large Study of Oncotype DX® to Quantify Risk of Loco-Regional Recurrence in Node-positive Breast Cancer Patients and Acceptance of Oncotype DX DCIS Validation Study for Publication investment picks
2013/4/17
Findings of CALGB 9581 Published in the Journal of Clinical Oncology Support Expansion of Colon Cancer Reimbursement and Broader Patient Access REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Publication of Second Positive Validation of Oncotype DX Colon Cancer Test Confirming Its Value Beyond Conventional Markers investment picks
2013/5/7
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference investment picks
2013/4/2
microRNA-based diagnostic assays for classifying renal cell tumors and for classifying tumors from patients with cancer of unknown or uncertain primary to be featured in poster session on April 7 PHILADELPHIA and REHOVOT, Israel , April 2, 2013 /PRNewswire/ -- Rosetta Genomics Ltd.
Sign-up for Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013 investment picks
2013/4/18
PHILADELPHIA and REHOVOT, Israel , April 18, 2013 /PRNewswire/ -- Rosetta Genomics Ltd.
Sign-up for Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories investment picks
2013/4/25
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 2, 2013 investment picks
2013/4/1
Unedited manuscript now available online PHILADELPHIA and REHOVOT, Israel , April 1, 2013 /PRNewswire/ -- Rosetta Genomics Ltd.
Sign-up for Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular Oncology investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Genomics Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Genetic Research  |  Next: Gentiva Health Services